+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report by Therapeutic Area (Neurological Disorders, Cardiovascular Disease), Technology (PCR, in-situ Hybridization), Region, with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 100 Pages
  • April 2025
  • Region: Global
  • Grand View Research
  • ID: 5893184
Description Jump to:
The Pharmacogenomics Technology Market was valued at USD 7.63 Billion in 2024, and is projected to reach USD 12.38 Billion by 2030, rising at a CAGR of 8.10%. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient’s therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights

  • Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
  • Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
  • Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
  • North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
  • Asia-Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
  • Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
  • In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Therapeutic area
1.2.2. Technology
1.2.3. Regional Scope
1.2.4. Estimates and Forecasts Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Therapeutic area outlook
2.2.2. Technology outlook
2.2.3. Regional outlook
2.3. Competitive Insights
Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Pharmacogenomics Technology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis
4.1. Therapeutic Area Dashboard
4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
4.4. Oncology
4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Lung Cancer
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Breast Cancer
4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Colorectal Cancer
4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.5. Cervical Cancer
4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.6. Others
4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.5. Neurological Disorders
4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.6. Cardiovascular Disorders
4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.7. Immunological Disorders
4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.8. Infectious Diseases
4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.9. Others
4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis
5.1. Technology Segment Dashboard
5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
5.4. PCR
5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.5. in-situ Hybridization
5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.6. Immunohistochemistry
5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.7. Sequencing
5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.8. Others
5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis
6.1. Regional Market Dashboard
6.2. Regional Market Share Analysis, 2024 & 2030
6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
6.4. North America
6.4.1. U.S.
6.4.1.1. Key country dynamics
6.4.1.2. Regulatory framework/ reimbursement structure
6.4.1.3. Competitive scenario
6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Canada
6.4.2.1. Key country dynamics
6.4.2.2. Regulatory framework/ reimbursement structure
6.4.2.3. Competitive scenario
6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Mexico
6.4.3.1. Key country dynamics
6.4.3.2. Regulatory framework/ reimbursement structure
6.4.3.3. Competitive scenario
6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
6.5. Europe
6.5.1. UK
6.5.1.1. Key country dynamics
6.5.1.2. Regulatory framework/ reimbursement structure
6.5.1.3. Competitive scenario
6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
6.5.2. Germany
6.5.2.1. Key country dynamics
6.5.2.2. Regulatory framework/ reimbursement structure
6.5.2.3. Competitive scenario
6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
6.5.3. France
6.5.3.1. Key country dynamics
6.5.3.2. Regulatory framework/ reimbursement structure
6.5.3.3. Competitive scenario
6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
6.5.4. Italy
6.5.4.1. Key country dynamics
6.5.4.2. Regulatory framework/ reimbursement structure
6.5.4.3. Competitive scenario
6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
6.5.5. Spain
6.5.5.1. Key country dynamics
6.5.5.2. Regulatory framework/ reimbursement structure
6.5.5.3. Competitive scenario
6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
6.5.6. Norway
6.5.6.1. Key country dynamics
6.5.6.2. Regulatory framework/ reimbursement structure
6.5.6.3. Competitive scenario
6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
6.5.7. Sweden
6.5.7.1. Key country dynamics
6.5.7.2. Regulatory framework/ reimbursement structure
6.5.7.3. Competitive scenario
6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
6.5.8. Denmark
6.5.8.1. Key country dynamics
6.5.8.2. Regulatory framework/ reimbursement structure
6.5.8.3. Competitive scenario
6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
6.6. Asia Pacific
6.6.1. Japan
6.6.1.1. Key country dynamics
6.6.1.2. Regulatory framework/ reimbursement structure
6.6.1.3. Competitive scenario
6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
6.6.2. China
6.6.2.1. Key country dynamics
6.6.2.2. Regulatory framework/ reimbursement structure
6.6.2.3. Competitive scenario
6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
6.6.3. India
6.6.3.1. Key country dynamics
6.6.3.2. Regulatory framework/ reimbursement structure
6.6.3.3. Competitive scenario
6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
6.6.4. Australia
6.6.4.1. Key country dynamics
6.6.4.2. Regulatory framework/ reimbursement structure
6.6.4.3. Competitive scenario
6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
6.6.5. South Korea
6.6.5.1. Key country dynamics
6.6.5.2. Regulatory framework/ reimbursement structure
6.6.5.3. Competitive scenario
6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
6.6.6. Thailand
6.6.6.1. Key country dynamics
6.6.6.2. Regulatory framework/ reimbursement structure
6.6.6.3. Competitive scenario
6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
6.7. Latin America
6.7.1. Brazil
6.7.1.1. Key country dynamics
6.7.1.2. Regulatory framework/ reimbursement structure
6.7.1.3. Competitive scenario
6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
6.7.2. Argentina
6.7.2.1. Key country dynamics
6.7.2.2. Regulatory framework/ reimbursement structure
6.7.2.3. Competitive scenario
6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
6.8. MEA
6.8.1. South Africa
6.8.1.1. Key country dynamics
6.8.1.2. Regulatory framework/ reimbursement structure
6.8.1.3. Competitive scenario
6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
6.8.2. Saudi Arabia
6.8.2.1. Key country dynamics
6.8.2.2. Regulatory framework/ reimbursement structure
6.8.2.3. Competitive scenario
6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
6.8.3. UAE
6.8.3.1. Key country dynamics
6.8.3.2. Regulatory framework/ reimbursement structure
6.8.3.3. Competitive scenario
6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
6.8.4. Kuwait
6.8.4.1. Key country dynamics
6.8.4.2. Regulatory framework/ reimbursement structure
6.8.4.3. Competitive scenario
6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, by Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.3.1. Key company heat map analysis, 2024
7.4. Company Profiles
7.4.1. QIAGEN
7.4.1.1. Company overview
7.4.1.2. Financial performance
7.4.1.3. Product benchmarking
7.4.1.4. Strategic initiatives
7.4.2. GE HealthCare
7.4.2.1. Company overview
7.4.2.2. Financial performance
7.4.2.3. Product benchmarking
7.4.2.4. Strategic initiatives
7.4.3. Agilent Technologies, Inc.
7.4.3.1. Company overview
7.4.3.2. Financial performance
7.4.3.3. Product benchmarking
7.4.3.4. Strategic initiatives
7.4.4. F. Hoffmann-La Roche Ltd
7.4.4.1. Company overview
7.4.4.2. Financial performance
7.4.4.3. Product benchmarking
7.4.4.4. Strategic initiatives
7.4.5. FOUNDATION MEDICINE, INC
7.4.5.1. Company overview
7.4.5.2. Financial performance
7.4.5.3. Product benchmarking
7.4.5.4. Strategic initiatives
7.4.6. Thermo Fisher Scientific Inc.
7.4.6.1. Company overview
7.4.6.2. Financial performance
7.4.6.3. Product benchmarking
7.4.6.4. Strategic initiatives
7.4.7. Oxford Nanopore Technologies plc.
7.4.7.1. Company overview
7.4.7.2. Financial performance
7.4.7.3. Product benchmarking
7.4.7.4. Strategic initiatives
7.4.8. Twist Bioscience
7.4.8.1. Company overview
7.4.8.2. Financial performance
7.4.8.3. Product benchmarking
7.4.8.4. Strategic initiatives
7.4.9. Leica Biosystems Nussloch GmBH
7.4.9.1. Company overview
7.4.9.2. Financial performance
7.4.9.3. Product benchmarking
7.4.9.4. Strategic initiatives
7.4.10. Pfizer Inc
7.4.10.1. Company overview
7.4.10.2. Financial performance
7.4.10.3. Product benchmarking
7.4.10.4. Strategic initiatives
7.4.11. Abbott
7.4.11.1. Company overview
7.4.11.2. Financial performance
7.4.11.3. Product benchmarking
7.4.11.4. Strategic initiatives
List of Tables
Table 1. List of abbreviations
Table 2. Global pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 3. Global pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 4. Global pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 5. North America pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 6. North America pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 7. North America pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 8. U.S. laboratory pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 9. U.S. pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 10. U.S. pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 11. Canada pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 12. Canada pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 13. Canada pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 14. Mexico pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 15. Mexico pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 16. Mexico pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 17. Europe pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 18. Europe pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 19. Europe pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 20. Germany pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 21. Germany pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 22. Germany pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 23. UK pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 24. UK pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 25. UK pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 26. France pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 27. France pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 28. France pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 29. Italy pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 30. Italy pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 31. Italy pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 32. Spain pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 33. Spain pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 34. Spain pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 35. Denmark pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 36. Denmark pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 37. Denmark pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 38. Sweden pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 39. Sweden pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 40. Sweden pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 41. Norway pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 42. Norway laboratory proficiency testing market, by technology, 2018-2030 (USD Million)
Table 43. Norway pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 44. Asia Pacific pharmacogenomics technology market, therapeutic area, 2018-2030 (USD Million)
Table 45. Asia Pacific pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 46. Asia Pacific pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 47. China pharmacogenomics technology market, therapeutic area, 2018-2030 (USD Million)
Table 48. China pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 49. China pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 50. Japan pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 51. Japan pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 52. Japan pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 53. India pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 54. India pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 55. India pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 56. South Korea pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 57. South Korea pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 58. South Korea pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 59. Australia pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 60. Australia pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 61. Australia pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 62. Thailand pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 63. Thailand pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 64. Thailand pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 65. Latin America pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 66. Latin America pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 67. Latin America pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 68. Brazil pharmacogenomics technology, therapeutic area, 2018-2030 (USD Million)
Table 69. Brazil pharmacogenomics technology, by technology, 2018-2030 (USD Million)
Table 70. Brazil pharmacogenomics technology, by region, 2018-2030 (USD Million)
Table 71. Argentina pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 72. Argentina pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 73. Argentina pharmacogenomics technology market, by end region, 2018-2030 (USD Million)
Table 74. MEA pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 75. MEA pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 76. MEA pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 77. South Africa pharmacogenomics technology testing market, by therapeutic area, 2018-2030 (USD Million)
Table 78. South Africa pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 79. South Africa pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 80. Saudi Arabia pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 81. Saudi Arabia pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 82. Saudi Arabia pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 83. UAE pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 84. UAE pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 85. UAE pharmacogenomics technology market, by region, 2018-2030 (USD Million)
Table 86. Kuwait pharmacogenomics technology market, by therapeutic area, 2018-2030 (USD Million)
Table 87. Kuwait pharmacogenomics technology market, by technology, 2018-2030 (USD Million)
Table 88. Kuwait pharmacogenomics technology market, by region, 2018-2030 (USD Million)
List of Figures
Figure 1 Market research process
Figure 2 Data triangulation techniques
Figure 3 Primary research pattern
Figure 4 Primary interviews
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 QFD modeling for market share assessment
Figure 8 Market formulation & validation
Figure 9 Pharmacogenomics technology: market outlook
Figure 10 Pharmacogenomics technology: competitive insights
Figure 11 Parent market outlook
Figure 12 Related/ancillary market outlook
Figure 13 Penetration and growth prospect mapping
Figure 14 Industry value chain analysis
Figure 15 Pharmacogenomics technology market driver impact
Figure 16 Pharmacogenomics technology market restraint impact
Figure 17 Pharmacogenomics technology market strategic initiatives analysis
Figure 18 Pharmacogenomics technology market: Therapeutic area analysis
Figure 19 Pharmacogenomics technology market: Therapeutic area outlook and key takeaways
Figure 20 Oncology market estimates and forecast, 2018-2030
Figure 21 Neurological disorders market estimates and forecast, 2018-2030
Figure 22 Cardiovascular diseases market estimates and forecast, 2018-2030
Figure 23 Immunological disorders market estimates and forecast, 2018-2030
Figure 24 Infectious diseases market estimates and forecast, 2018-2030
Figure 25 Others market estimates and forecast, 2018-2030
Figure 26 Pharmacogenomics technology market: Technology movement analysis
Figure 27 Pharmacogenomics technology market: Technology outlook and key takeaways
Figure 28 PCR market estimates and forecasts, 2018-2030
Figure 29 In-situ hybridization market estimates and forecasts, 2018-2030
Figure 30 Immunohistochemistry market estimates and forecasts, 2018-2030
Figure 31 Sequencing market estimates and forecasts, 2018-2030
Figure 32 Others market estimates and forecasts, 2018-2030
Figure 33 Global Pharmacogenomics technology market: Regional movement analysis
Figure 34 Global Pharmacogenomics technology market: Regional outlook and key takeaways
Figure 35 North America market estimates and forecasts, 2018-2030
Figure 36 U.S. market estimates and forecasts, 2018-2030
Figure 37 Canada market estimates and forecasts, 2018-2030
Figure 38 Mexico market estimates and forecasts, 2018-2030
Figure 39 Europe market estimates and forecasts, 2018-2030
Figure 40 UK market estimates and forecasts, 2018-2030
Figure 41 Germany market estimates and forecasts, 2018-2030
Figure 42 France market estimates and forecasts, 2018-2030
Figure 43 Italy market estimates and forecasts, 2018-2030
Figure 44 Spain market estimates and forecasts, 2018-2030
Figure 45 Denmark market estimates and forecasts, 2018-2030
Figure 46 Sweden market estimates and forecasts, 2018-2030
Figure 47 Norway market estimates and forecasts, 2018-2030
Figure 48 Asia Pacific market estimates and forecasts, 2018-2030
Figure 49 China market estimates and forecasts, 2018-2030
Figure 50 Japan market estimates and forecasts, 2018-2030
Figure 51 India market estimates and forecasts, 2018-2030
Figure 52 Thailand market estimates and forecasts, 2018-2030
Figure 53 South Korea market estimates and forecasts, 2018-2030
Figure 54 Australia market estimates and forecasts, 2018-2030
Figure 55 Latin America market estimates and forecasts, 2018-2030
Figure 56 Brazil market estimates and forecasts, 2018-2030
Figure 57 Argentina market estimates and forecasts, 2018-2030
Figure 58 Middle East and Africa market estimates and forecasts, 2018-2030
Figure 59 South Africa market estimates and forecasts, 2018-2030
Figure 60 Saudi Arabia market estimates and forecasts, 2018-2030
Figure 61 UAE market estimates and forecasts, 2018-2030
Figure 62 Kuwait market estimates and forecasts, 2018-2030

Companies Mentioned

The companies profiled in this Pharmacogenomics Technology market report include:
  • QIAGEN
  • GE HealthCare
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC.
  • Thermo Fisher Scientific Inc.
  • Oxford Nanopore Technologies plc.
  • Twist Bioscience
  • Leica Biosystems Nussloch GmBH
  • Pfizer Inc.
  • Abbott

Table Information

Report AttributeDetails
No. of Pages100
PublishedApril 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 7.63 Billion
Forecasted Market Value ( USD ) by 2030 $ 12.38 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned12

Related Topics

Related Reports

Molecular Diagnostics in Pharmacogenomics Market Size, Share & Trends Analysis Report by Product (Kits & Assays, Reagents, Services), by Therapeutic Area, by Technology, by Region, and Segment Forecasts, 2025-2033 - Product Image

Molecular Diagnostics in Pharmacogenomics Market Size, Share & Trends Analysis Report by Product (Kits & Assays, Reagents, Services), by Therapeutic Area, by Technology, by Region, and Segment Forecasts, 2025-2033

  • Report
  • 150 Pages
  • Global
From
Pharmacogenomics Services Market - Global Forecast to 2030 - Product Image

Pharmacogenomics Services Market - Global Forecast to 2030

  • Report
  • 196 Pages
  • Global
From
Molecular Diagnostics In Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2020-2030F - Product Image

Molecular Diagnostics In Pharmacogenomics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Pharmacogenomics Technology - Global Strategic Business Report - Product Image

Pharmacogenomics Technology - Global Strategic Business Report

  • Report
  • 291 Pages
  • Global
From
Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Pharmacogenomics Technology Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.